# AOD-9604 dosage guide

> Review AOD-9604 dosage information by administration route, with source-linked dose and schedule details.

Canonical: https://pepflow.app/peptides/aod-9604/dosage/

Compare oral AOD-9604 amounts with injection schedules, including timing, course lengths and gradual injection progressions. Calculate volume and syringe units using your own vial inputs.

[Full AOD-9604 library reference](<https://pepflow.app/peptides/aod-9604/>)

## AOD-9604 dosage chart

This summary table compares available dose amounts and schedules by administration route.

| Route | Dose | Frequency & duration |
| --- | --- | --- |
| Oral | ~1 mg | Daily · ~24 wk |
| Injectable | 250–500 mcg | 1–2x daily · 8–12 wk |

## AOD-9604 dosage by administration route

### AOD-9604 oral dosage

Reported-use amounts for AOD-9604 are ~1 mg per administration, daily, for approximately 24 wk.[\[8\]](<https://pepflow.app/peptides/aod-9604/dosage/#source-8>)

AOD-9604 is a modified growth-hormone fragment associated with fat-metabolism signaling. It is a different molecule from the native HGH fragment 176–191 and does not provide full growth-hormone replacement.[\[7\]](<https://pepflow.app/peptides/aod-9604/dosage/#source-7>) [\[1\]](<https://pepflow.app/peptides/aod-9604/dosage/#source-1>) [\[2\]](<https://pepflow.app/peptides/aod-9604/dosage/#source-2>) [\[8\]](<https://pepflow.app/peptides/aod-9604/dosage/#source-8>)

### AOD-9604 injectable dosage

Reported-use amounts for AOD-9604 are 250–500 mcg per administration, 1–2x daily, for 8–12 wk. One reported once-daily subcutaneous progression uses 250 mcg during weeks 1–4, followed by 500 mcg during weeks 5–12. This describes an 8–12-week course without the twice-daily frequency of some other reported patterns.[\[8\]](<https://pepflow.app/peptides/aod-9604/dosage/#source-8>) [\[9\]](<https://pepflow.app/peptides/aod-9604/dosage/#source-9>)

AOD-9604 is a modified growth-hormone fragment associated with fat-metabolism signaling. It is a different molecule from the native HGH fragment 176–191 and does not provide full growth-hormone replacement.[\[3\]](<https://pepflow.app/peptides/aod-9604/dosage/#source-3>) [\[4\]](<https://pepflow.app/peptides/aod-9604/dosage/#source-4>) [\[1\]](<https://pepflow.app/peptides/aod-9604/dosage/#source-1>) [\[2\]](<https://pepflow.app/peptides/aod-9604/dosage/#source-2>) [\[8\]](<https://pepflow.app/peptides/aod-9604/dosage/#source-8>)

### Frequency and timing

Morning is the listed timing for oral use. Injections are commonly timed in the morning or before a workout.[\[5\]](<https://pepflow.app/peptides/aod-9604/dosage/#source-5>) [\[6\]](<https://pepflow.app/peptides/aod-9604/dosage/#source-6>) [\[7\]](<https://pepflow.app/peptides/aod-9604/dosage/#source-7>) [\[8\]](<https://pepflow.app/peptides/aod-9604/dosage/#source-8>)

### Cycle length and breaks

Oral: ~24 wk. Injectable: 8–12 wk. A standard break interval between courses is not established.[\[8\]](<https://pepflow.app/peptides/aod-9604/dosage/#source-8>)

## AOD-9604 dosage calculator

Convert your chosen AOD-9604 amount into volume and U-100 syringe units. Adjust the inputs to match your vial and preparation.

For preparation terms and concentration basics, see the [reconstitution guidelines](<https://pepflow.app/peptide-reconstitution-guidelines/>). Follow the arithmetic in the [concentration calculation walkthrough](<https://pepflow.app/blog/how-to-calculate-final-concentration/>).

## AOD-9604 safety and side effects

### Approval and product quality

AOD-9604 is not an FDA-approved drug.[\[4\]](<https://pepflow.app/peptides/aod-9604/dosage/#source-4>) [\[3\]](<https://pepflow.app/peptides/aod-9604/dosage/#source-3>)

### Side effects and long-term safety

Human long-term safety, dose-response and route-specific risks remain unresolved. Clinical usefulness is limited; product purity and FDA compounding concerns require separate attention.[\[3\]](<https://pepflow.app/peptides/aod-9604/dosage/#source-3>) [\[4\]](<https://pepflow.app/peptides/aod-9604/dosage/#source-4>)

### Route-specific dosing limits

The main cautions are FDA compounding safety concerns, unapproved-product quality, sports prohibition, and missing safety support for special populations. Reported-use oral and injectable schedules and additional protocol patterns are not established human treatment regimens or approved product instructions.[\[3\]](<https://pepflow.app/peptides/aod-9604/dosage/#source-3>) [\[4\]](<https://pepflow.app/peptides/aod-9604/dosage/#source-4>) [\[9\]](<https://pepflow.app/peptides/aod-9604/dosage/#source-9>) [\[8\]](<https://pepflow.app/peptides/aod-9604/dosage/#source-8>)

## Common AOD-9604 dosage questions

### Can AOD-9604 doses be transferred between routes?

No. Each route and formulation has its own exposure and administration requirements. Use the dose information for the exact presentation rather than copying a tablet, injection or local-product amount to another route.[\[7\]](<https://pepflow.app/peptides/aod-9604/dosage/#source-7>) [\[3\]](<https://pepflow.app/peptides/aod-9604/dosage/#source-3>) [\[6\]](<https://pepflow.app/peptides/aod-9604/dosage/#source-6>)

### What dosage is listed for AOD-9604?

Reported-use amounts for AOD-9604 are ~1 mg per administration, daily, for approximately 24 wk.[\[8\]](<https://pepflow.app/peptides/aod-9604/dosage/#source-8>)

### Does AOD-9604 have a standard cycle or break interval?

Oral: ~24 wk. Injectable: 8–12 wk. A standard break interval between courses is not established.[\[8\]](<https://pepflow.app/peptides/aod-9604/dosage/#source-8>)

## Sources

- [\[1\] **Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism** American Journal of Physiology-Endocrinology and Metabolism. animal.](<https://pubmed.ncbi.nlm.nih.gov/10950816/>)
- [\[2\] **Metabolic studies of a synthetic lipolytic domain of human growth hormone in obese Zucker rats** Endocrinology / metabolic research. animal.](<https://pubmed.ncbi.nlm.nih.gov/11146367/>)
- [\[3\] **Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks** U.S. Food and Drug Administration, 2026-04-22. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)
- [\[4\] **Search Drugs@FDA for AOD-9604** openFDA / U.S. Food and Drug Administration. database query.](<https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>)
- [\[5\] **AOD-9604 Metabolic** Drugs in R&D. review.](<https://pubmed.ncbi.nlm.nih.gov/15134286/>)
- [\[6\] **Obesity pharmacotherapy: current perspectives and future directions** Current Obesity Reports / PMC. review.](<https://pmc.ncbi.nlm.nih.gov/articles/PMC3584306/>)
- [\[7\] **Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans** Journal of Endocrinology and Metabolism, 2013-04. human clinical.](<https://www.jofem.org/index.php/jofem/article/view/157/194>)
- [\[8\] **PepFlow peptide cheat sheet — reported-use and product-orientation reference (not clinical research)** PepFlow. reference catalog.](<https://pepflow.app/peptide-cheat-sheet/>)
- [\[9\] **AOD-9604 — Everything Peptide reported protocol (educational reference, not clinical evidence)** Everything Peptide. reference catalog.](<https://everythingpeptide.com/protocol-aod-9604.html>)

[Full AOD-9604 library reference →](<https://pepflow.app/peptides/aod-9604/>)

## Related

- [AOD-9604 Peptide](<https://pepflow.app/peptides/aod-9604/>)
- [Peptide reconstitution guidelines](<https://pepflow.app/peptide-reconstitution-guidelines/>)
- [How to Calculate Final Concentration: A Practical Guide](<https://pepflow.app/blog/how-to-calculate-final-concentration/>)
- [Peptide Cheat Sheet](<https://pepflow.app/peptide-cheat-sheet/>)
